How to buy Momenta Pharmaceuticals stock

Momenta Pharmaceuticals, Inc is a drug manufacturers—specialty & generic business based in the US. Momenta Pharmaceuticals shares (MNTA) are listed on the NASDAQ and all prices are listed in US Dollars. Momenta Pharmaceuticals employs 118 staff and has a trailing 12-month revenue of around USD$30.1 million.

How to buy shares in Momenta Pharmaceuticals

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Momenta Pharmaceuticals. Find the stock by name or ticker symbol: MNTA. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Momenta Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Momenta Pharmaceuticals, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Momenta Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Momenta Pharmaceuticals share price

Use our graph to track the performance of MNTA stocks over time.

Momenta Pharmaceuticals shares at a glance

• Key figures

Information last updated 2020-11-22.

52-week range	USD$15.31 - USD$52.53
50-day moving average	USD$52.3753
200-day moving average	USD$37.7275
Wall St. target price	USD$52.5
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-2.441

Buy Momenta Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Momenta Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Momenta Pharmaceuticals, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Momenta Pharmaceuticals financials

Revenue TTM	USD$30.1 million
Gross profit TTM	USD$-73,756,000
Return on assets TTM	-30.56%
Return on equity TTM	0%
Profit margin	0%
Book value	$3.406
Market capitalisation	USD$6.2 billion

TTM: trailing 12 months

Shorting Momenta Pharmaceuticals shares

There are currently 5.4 million Momenta Pharmaceuticals shares held short by investors – that's known as Momenta Pharmaceuticals's "short interest". This figure is 23% up from 4.4 million last month.

There are a few different ways that this level of interest in shorting Momenta Pharmaceuticals shares can be evaluated.

Momenta Pharmaceuticals's "short interest ratio" (SIR)

Momenta Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Momenta Pharmaceuticals shares currently shorted divided by the average quantity of Momenta Pharmaceuticals shares traded daily (recently around 6.9 million). Momenta Pharmaceuticals's SIR currently stands at 0.79. In other words for every 100,000 Momenta Pharmaceuticals shares traded daily on the market, roughly 790 shares are currently held short.

However Momenta Pharmaceuticals's short interest can also be evaluated against the total number of Momenta Pharmaceuticals shares, or, against the total number of tradable Momenta Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Momenta Pharmaceuticals's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Momenta Pharmaceuticals shares in existence, roughly 50 shares are currently held short) or 0.0757% of the tradable shares (for every 100,000 tradable Momenta Pharmaceuticals shares, roughly 76 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Momenta Pharmaceuticals.

Find out more about how you can short Momenta Pharmaceuticals stock.

Momenta Pharmaceuticals share dividends

We're not expecting Momenta Pharmaceuticals to pay a dividend over the next 12 months.

Momenta Pharmaceuticals share price volatility

Over the last 12 months, Momenta Pharmaceuticals's shares have ranged in value from as little as $15.31 up to $52.53. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Momenta Pharmaceuticals's is 1.7854. This would suggest that Momenta Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Momenta Pharmaceuticals overview

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy. The company's biosimilar programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M710, a biosimilar of EYLEA for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema (DME), and diabetic retinopathy in patients with DME. Its complex generics programs include Enoxaparin sodium injection, a generic version of LOVENOX that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing forms of multiple sclerosis; and GLATOPA, a generic version of three-times-weekly COPAXONE. The company has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts. As of September 30, 2020, Momenta Pharmaceuticals, Inc. operates as a subsidiary of Johnson & Johnson.

Frequently asked questions

• What percentage of Momenta Pharmaceuticals is owned by insiders or institutions?

  Currently 0.984% of Momenta Pharmaceuticals shares are held by insiders and 103.484% by institutions.

• How many people work for Momenta Pharmaceuticals?

  Latest data suggests 118 work at Momenta Pharmaceuticals.

• When does the fiscal year end for Momenta Pharmaceuticals?

  Momenta Pharmaceuticals's fiscal year ends in December.

• Where is Momenta Pharmaceuticals based?

  Momenta Pharmaceuticals's address is: 301 Binney Street, Cambridge, MA, United States, 02142

• What is Momenta Pharmaceuticals's ISIN number?

  Momenta Pharmaceuticals's international securities identification number is: US60877T1007

• What is Momenta Pharmaceuticals's CUSIP number?

  Momenta Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 60877T100